NL-OMON21051
Not yet recruiting
Not Applicable
The OPTIMAL study:<br>Optimizing Performance of afiniTor by splitting Intake Moments and decreasing Adverse events whilst maintainingoutcome quaLity.
etherlands Cancer Intitute0 sites10 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Advanced hormone positive, HER2 negative, breast cancer.
- Sponsor
- etherlands Cancer Intitute
- Enrollment
- 10
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age \>18 years;
- •2\.Able and willing to give written informed consent;
Exclusion Criteria
- •1\.Woman who are pregnant or breast feeding;
- •2\.Known hypersensitivity to any of the study drugs or excipients;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
The OPTIMAL study: Optimizing Performance of afiniTor by splitting Intake Moments and decreasing Adverse events whilst maintaining outcome quaLity.Breast CancerHER-2 negativeHormone Positieve10006291NL-OMON41877Antoni van Leeuwenhoek Ziekenhuis10
Not yet recruiting
Not Applicable
An evaluation and an examination of the optimization of the cancer immunotherapy for advanced non-small cell lung cancerPatients with advanced non-small cell lung cancer who are going to receive a therapy with immune checkpoint InhibitorsJPRN-UMIN000031127Tohoku Medical and Pharmaceutical University,Tohoku Medical and Pharmaceutical University Hospital20
Recruiting
Not Applicable
Fabrication and assessment the effect of optimized radiation shield made of silicone-barium sulfate on radiation dose of breast in thoracic CT imagingIRCT20230413057892N1Gonabad University of Medical Sciences23
Completed
Not Applicable
The study of looking for the optimal evaluation method of clinical activity by using new UC-Capsule Endoscopic Sore (UCCAS) LUCCAS studylcerative colitisJPRN-UMIN000016156Saitama Medical Center, Saitama Medical University20
Completed
Not Applicable
Evaluation of the safety and efficacy of the Optimizer™ II and III systems with active fixation leads in subjects with heart failure resulting from systolic dysfunctioHeart failureCirculatory SystemISRCTN16213127Impulse Dynamics Inc. (USA)250